Search
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948Experimental25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It...
Pentoxyverine
go.drugbank.com/drugs/DB11186ApprovedWithdrawnIt is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160].
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalThe advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[L31588] CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard therapy. … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.
Cyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigationalCyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in ...
Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnIt is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency
Trimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigationalTrimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angin...
Lowbush blueberry
go.drugbank.com/drugs/DB14229InvestigationalIngredient used in over-the-counter medications.